• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

S100A8作为肿瘤微环境中有前景的生物标志物和致癌免疫蛋白：一项泛癌综合分析

S100A8 as a Promising Biomarker and Oncogenic Immune Protein in the Tumor Microenvironment: An Integrative Pancancer Analysis.

作者信息

Wu Zixuan, Jiang Dongli, Huang Xuyan, Cai Minjie, Yuan Kai, Huang Peidong

机构信息

Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China 510006S.

The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong Province, China 510009.

出版信息

J Oncol. 2022 Mar 18;2022:6947652. doi: 10.1155/2022/6947652. eCollection 2022.

DOI:10.1155/2022/6947652
PMID:35646116
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9132702/
Abstract

BACKGROUND

S100 Calcium Binding Protein A8 (S100A8) is beneficial for cancer immunotherapy. However, the processes underlying its therapeutic potential have not been completely studied.

METHODS

The Cancer Genome Atlas provides raw data on 33 different cancer types. GEO made available GSE67501, GSE78220, and IMvigor210. We investigated S100A8's genetic changes, expression patterns, and survival studies. The linkages between S100A8 and TME, as well as its association with immunological processes/elements and the major histocompatibility complex, were explored to effectively understand the role of S100A8 in cancer immunotherapy. Three distinct immunotherapeutic cohorts were employed to examine the relationship between S100A8 and immunotherapeutic response.

RESULTS

S100A8 expression was high in tumor tissue. The overexpression of S100A8 is associated with poor clinical outcome in patients with overall survival. S100A8 is associated with immune cell infiltration, immunological modulators, and immunotherapeutic indicators. S100A8 overexpression is connected to immune-related pathways. However, no statistically significant connection between S100A8 and immunotherapeutic response was identified.

CONCLUSIONS

S100A8 may be a reliable biomarker for tumor prognosis and a viable prospective therapeutic target for human cancer immunotherapy (e.g., GBM, KIRC, LGG, and LIHC).

摘要

背景

S100钙结合蛋白A8（S100A8）对癌症免疫治疗有益。然而，其治疗潜力背后的机制尚未得到充分研究。

方法

癌症基因组图谱提供了33种不同癌症类型的原始数据。基因表达综合数据库提供了GSE67501、GSE78220和IMvigor210。我们研究了S100A8的基因变化、表达模式和生存情况。探索了S100A8与肿瘤微环境之间的联系，以及它与免疫过程/元素和主要组织相容性复合体的关联，以有效了解S100A8在癌症免疫治疗中的作用。采用三个不同的免疫治疗队列来研究S100A8与免疫治疗反应之间的关系。

结果

S100A8在肿瘤组织中高表达。S100A8的过表达与总体生存患者的不良临床结局相关。S100A8与免疫细胞浸润、免疫调节剂和免疫治疗指标相关。S100A8的过表达与免疫相关途径有关。然而，未发现S100A8与免疫治疗反应之间存在统计学上的显著关联。

结论

S100A8可能是肿瘤预后的可靠生物标志物，也是人类癌症免疫治疗（如胶质母细胞瘤、肾透明细胞癌、脑低级别胶质瘤和肝细胞癌）可行的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/13032dfdd0a8/JO2022-6947652.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/b778ee3917a0/JO2022-6947652.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/97a5c9de9714/JO2022-6947652.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/74ff879cfb08/JO2022-6947652.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/a485a5a024e4/JO2022-6947652.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/1bca59e397c7/JO2022-6947652.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/3dfa7a474d66/JO2022-6947652.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/003513b006c0/JO2022-6947652.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/c969547fe5fe/JO2022-6947652.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/450e90ed9671/JO2022-6947652.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/0e9b305459b0/JO2022-6947652.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/20cbaecbac4f/JO2022-6947652.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/13032dfdd0a8/JO2022-6947652.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/b778ee3917a0/JO2022-6947652.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/97a5c9de9714/JO2022-6947652.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/74ff879cfb08/JO2022-6947652.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/a485a5a024e4/JO2022-6947652.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/1bca59e397c7/JO2022-6947652.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/3dfa7a474d66/JO2022-6947652.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/003513b006c0/JO2022-6947652.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/c969547fe5fe/JO2022-6947652.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/450e90ed9671/JO2022-6947652.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/0e9b305459b0/JO2022-6947652.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/20cbaecbac4f/JO2022-6947652.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f62/9132702/13032dfdd0a8/JO2022-6947652.012.jpg

相似文献

1
S100A8 as a Promising Biomarker and Oncogenic Immune Protein in the Tumor Microenvironment: An Integrative Pancancer Analysis.S100A8作为肿瘤微环境中有前景的生物标志物和致癌免疫蛋白：一项泛癌综合分析
J Oncol. 2022 Mar 18;2022:6947652. doi: 10.1155/2022/6947652. eCollection 2022.
2
In the Tumor Microenvironment, ETS1 Is an Oncogenic Immune Protein: An Integrative Pancancer Analysis.在肿瘤微环境中，ETS1是一种致癌免疫蛋白：一项泛癌综合分析。
Evid Based Complement Alternat Med. 2022 Apr 15;2022:7730433. doi: 10.1155/2022/7730433. eCollection 2022.
3
A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.全面泛癌分析 33 种人类癌症揭示芳香烃受体的免疫治疗价值
Front Immunol. 2021 Jul 5;12:564948. doi: 10.3389/fimmu.2021.564948. eCollection 2021.
4
Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase.全面泛癌症分析 33 种人类癌症揭示粘着斑激酶的免疫治疗价值。
Medicine (Baltimore). 2024 Mar 22;103(12):e37362. doi: 10.1097/MD.0000000000037362.
5
Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types.33种癌症类型中m5C调节因子NOP2的分子特征、临床及免疫治疗特征
Front Cell Dev Biol. 2022 Mar 16;10:839136. doi: 10.3389/fcell.2022.839136. eCollection 2022.
6
S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma.S100A8是一种预后标志物，与弥漫性大B细胞淋巴瘤中的免疫反应相关。
Front Oncol. 2024 Feb 1;14:1344669. doi: 10.3389/fonc.2024.1344669. eCollection 2024.
7
Prognostic and immunotherapeutic significance of mannose receptor C type II in 33 cancers: An integrated analysis.甘露糖受体C型II在33种癌症中的预后及免疫治疗意义：一项综合分析
Front Mol Biosci. 2022 Sep 14;9:951636. doi: 10.3389/fmolb.2022.951636. eCollection 2022.
8
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.泛癌分析 PARP1 改变作为预测免疫治疗效果的生物标志物及其表达水平与免疫治疗特征的关联。
Front Immunol. 2021 Aug 31;12:721030. doi: 10.3389/fimmu.2021.721030. eCollection 2021.
9
Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.鉴定SHCBP1作为一种潜在的生物标志物，涉及多种癌症的诊断、预后及肿瘤免疫微环境。
Comput Struct Biotechnol J. 2022 Jun 18;20:3106-3119. doi: 10.1016/j.csbj.2022.06.039. eCollection 2022.
10
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.肿瘤微环境衍生的 S100A8/A9 是晚期黑色素瘤患者和抗 PD-1 抗体免疫治疗的新型预后生物标志物。
J Immunother Cancer. 2019 Dec 5;7(1):343. doi: 10.1186/s40425-019-0828-1.

引用本文的文献

1
Single-cell transcriptome dissecting the microenvironment remodeled by PD1 blockade combined with photodynamic therapy in a mouse model of oral carcinogenesis.单细胞转录组剖析口腔癌发生小鼠模型中PD1阻断联合光动力疗法重塑的微环境。
MedComm (2020). 2024 Jul 2;5(7):e636. doi: 10.1002/mco2.636. eCollection 2024 Jul.
2
Single-cell profiling reveals the metastasis-associated immune signature of hepatocellular carcinoma.单细胞分析揭示了肝癌转移相关的免疫特征。
Immun Inflamm Dis. 2024 May;12(5):e1264. doi: 10.1002/iid3.1264.
3
S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma.

本文引用的文献

1
Low social and family well-being is associated with greater RAGE ligand s100A8/A9 and interleukin-1 beta levels in metastatic breast cancer patients.社会和家庭幸福感较低与转移性乳腺癌患者中更高水平的RAGE配体s100A8/A9和白细胞介素-1β相关。
Brain Behav Immun Health. 2022 Feb 22;21:100433. doi: 10.1016/j.bbih.2022.100433. eCollection 2022 May.
2
S100A8/A9 Enhances Immunomodulatory and Tissue-Repairing Properties of Human Amniotic Mesenchymal Stem Cells in Myocardial Ischemia-Reperfusion Injury.S100A8/A9 增强人羊膜间充质干细胞在心肌缺血再灌注损伤中的免疫调节和组织修复特性。
Int J Mol Sci. 2021 Oct 16;22(20):11175. doi: 10.3390/ijms222011175.
3
S100A8是一种预后标志物，与弥漫性大B细胞淋巴瘤中的免疫反应相关。
Front Oncol. 2024 Feb 1;14:1344669. doi: 10.3389/fonc.2024.1344669. eCollection 2024.
4
CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer.CD69是癌症中一个有前景的免疫治疗和预后预测靶点。
Immunotargets Ther. 2024 Jan 9;13:1-14. doi: 10.2147/ITT.S439969. eCollection 2024.
5
The functions and regulatory pathways of S100A8/A9 and its receptors in cancers.S100A8/A9及其受体在癌症中的功能与调控途径
Front Pharmacol. 2023 Aug 28;14:1187741. doi: 10.3389/fphar.2023.1187741. eCollection 2023.
6
S100 proteins in head and neck squamous cell carcinoma (Review).头颈部鳞状细胞癌中的S100蛋白（综述）
Oncol Lett. 2023 Jul 6;26(2):362. doi: 10.3892/ol.2023.13948. eCollection 2023 Aug.
7
Quantitative tissue proteome profile reveals neutrophil degranulation and remodeling of extracellular matrix proteins in early stage gallbladder cancer.定量组织蛋白质组图谱揭示早期胆囊癌中性粒细胞脱颗粒及细胞外基质蛋白重塑
Front Oncol. 2023 Jan 6;12:1046974. doi: 10.3389/fonc.2022.1046974. eCollection 2022.
3D stochastic microsensors for molecular recognition and determination of heregulin-α in biological samples.
用于生物样本中表皮生长因子受体配体-α的分子识别和测定的 3D 随机微传感器。
Anal Bioanal Chem. 2021 May;413(13):3487-3492. doi: 10.1007/s00216-021-03295-7. Epub 2021 Mar 24.
4
S100A8 promotes epithelial-mesenchymal transition and metastasis under TGF-β/USF2 axis in colorectal cancer.S100A8 通过 TGF-β/USF2 轴促进结直肠癌细胞上皮-间质转化和转移。
Cancer Commun (Lond). 2021 Feb;41(2):154-170. doi: 10.1002/cac2.12130. Epub 2021 Jan 3.
5
Prognostic Role of S100A8 in Human Solid Cancers: A Systematic Review and Validation.S100A8在人类实体癌中的预后作用：一项系统评价与验证
Front Oncol. 2020 Nov 9;10:564248. doi: 10.3389/fonc.2020.564248. eCollection 2020.
6
The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.S100A8/A9 异二聚体是特发性肺纤维化的一个有效治疗靶点。
J Mol Med (Berl). 2021 Jan;99(1):131-145. doi: 10.1007/s00109-020-02001-x. Epub 2020 Nov 9.
7
Immunometabolic Interplay in the Tumor Microenvironment.肿瘤微环境中的免疫代谢相互作用
Cancer Cell. 2021 Jan 11;39(1):28-37. doi: 10.1016/j.ccell.2020.09.004. Epub 2020 Oct 29.
8
Stochastic microsensors for the assessment of DNA damage in cancer.用于评估癌症中 DNA 损伤的随机微传感器。
Anal Biochem. 2020 Sep 15;605:113839. doi: 10.1016/j.ab.2020.113839. Epub 2020 Jul 20.
9
Donor monocyte-derived macrophages promote human acute graft-versus-host disease.供者单核细胞衍生的巨噬细胞促进人类急性移植物抗宿主病。
J Clin Invest. 2020 Sep 1;130(9):4574-4586. doi: 10.1172/JCI133909.
10
Suppressive effects of S100A8 and S100A9 on neutrophil apoptosis by cytokine release of human bronchial epithelial cells in asthma.哮喘患者气道上皮细胞细胞因子释放对中性粒细胞凋亡的抑制作用及 S100A8、S100A9 的影响。
Int J Med Sci. 2020 Feb 4;17(4):498-509. doi: 10.7150/ijms.37833. eCollection 2020.